Since the discovery of the Human Immunodeficiency Virus type 1 (HIV-1) as the cause of Acquired Immunodeficiency Syndrome (AIDS) almost 30 years, nearly 25 million people have died from AIDS worldwide. HIV-1/AIDS is a pandemic and there currently is no vaccine or cure for the devastating disease. Regardless of the route of infection, the mucosa is the primary site of viral replication and amplification. Therefore, the generation of immune responses at mucosal sites by and HIV-1 vaccine is likely important. We aimed to modulate the immune response generated through systemic vaccination by incorporating plasmid DNA expressing cytokine or mucosal chemokine adjuvants. First, we examined the potential of IL-15 in combination with its high affini...
Background An effective HIV vaccine will likely require induction of both mucosal and systemic cellu...
<div><p>Background</p><p>An effective HIV vaccine will likely require induction of both mucosal and ...
The HIV vaccines tested in the halted Step efficacy trial and the modestly successful phase 3 RV144 ...
Since the discovery of the Human Immunodeficiency Virus type 1 (HIV-1) as the cause of Acquired Immu...
Immunotherapies that induce durable immune control of chronic HIV infection may eliminate the need f...
Immunotherapies that induce durable immune control of chronic HIV infection may eliminate the need f...
Immunotherapies that induce durable immune control of chronic HIV infection may eliminate the need f...
Immunotherapies that induce durable immune control of chronic HIV infection may eliminate the need f...
Introduction: Traditional vaccine strategies are inefficient at protecting against more complex path...
An effective HIV vaccine will likely require induction of both mucosal and systemic cellular and hum...
Development of a successful vaccine against HIV is likely to require the induction of strong and lon...
AbstractIn this report, we described induction of HIV envelope (env)-specific systemic and mucosal i...
The appalling toll on the populations of developing countries as a result of the HIV epidemic shows ...
Thesis (Ph.D.)--University of Washington, 2021A therapeutic vaccine that induces lasting control of ...
An effective HIV vaccine will likely require induction of both mucosal and systemic cellular and hum...
Background An effective HIV vaccine will likely require induction of both mucosal and systemic cellu...
<div><p>Background</p><p>An effective HIV vaccine will likely require induction of both mucosal and ...
The HIV vaccines tested in the halted Step efficacy trial and the modestly successful phase 3 RV144 ...
Since the discovery of the Human Immunodeficiency Virus type 1 (HIV-1) as the cause of Acquired Immu...
Immunotherapies that induce durable immune control of chronic HIV infection may eliminate the need f...
Immunotherapies that induce durable immune control of chronic HIV infection may eliminate the need f...
Immunotherapies that induce durable immune control of chronic HIV infection may eliminate the need f...
Immunotherapies that induce durable immune control of chronic HIV infection may eliminate the need f...
Introduction: Traditional vaccine strategies are inefficient at protecting against more complex path...
An effective HIV vaccine will likely require induction of both mucosal and systemic cellular and hum...
Development of a successful vaccine against HIV is likely to require the induction of strong and lon...
AbstractIn this report, we described induction of HIV envelope (env)-specific systemic and mucosal i...
The appalling toll on the populations of developing countries as a result of the HIV epidemic shows ...
Thesis (Ph.D.)--University of Washington, 2021A therapeutic vaccine that induces lasting control of ...
An effective HIV vaccine will likely require induction of both mucosal and systemic cellular and hum...
Background An effective HIV vaccine will likely require induction of both mucosal and systemic cellu...
<div><p>Background</p><p>An effective HIV vaccine will likely require induction of both mucosal and ...
The HIV vaccines tested in the halted Step efficacy trial and the modestly successful phase 3 RV144 ...